 CAMBRIDGE, Mass., May 11, 2021 GLOBE NEWSWIRE -- Praxis Precision Medicines, Inc. NASDAQ: PRAX, a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders CNS characterized by neuronal imbalance, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. Praxis also intends to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of its common stock sold in the public offering. All shares in the offering are to be sold by Praxis. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. 